SCHEMBL4677016

SCHEMBL4677016

O=C(C=C(O)c1nn[nH]n1)c1ccc(Cc2ccncc2)o1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.34
NCEH1 Q6PIU2 1/20 0.34
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
MMEL1 Q495T6 3/20 0.32
LMNA P02545 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
FFAR2 O15552 1/20 0.31
TSHR P16473 1/20 0.31
CYP17A1 P05093 1/20 0.31
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
MME P08473 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671110 0.91 CES1 (0.43) CES1NCEH1MMEL1HDAC1HDAC6
SCHEMBL4671648 0.89 CES1 (0.34) CES1NCEH1MMEL1LMNAMME
SCHEMBL4673269 0.89 ALDH1A1 (0.40) CES1NCEH1MMEL1LMNAHTT
SCHEMBL4674475 0.89 CES1 (0.34) CES1NCEH1MMEL1ERCC5FEN1
SCHEMBL4673268 0.87 XDH (0.40) CES1NCEH1MMEL1LMNATSHR
SCHEMBL4675745 0.86 ALDH1A1 (0.43) LMNATSHRERCC5FEN1HTT
SCHEMBL4678671 0.83 ALDH1A1 (0.38) CES1NCEH1MMEL1LMNAHDAC1
SCHEMBL4674742 0.82 HCAR2 (0.40) CES1NCEH1MMEL1LMNAFFAR2
SCHEMBL4671675 0.82 LMNA (0.34) CYP11B1CYP11B2LMNAHDAC1HDAC6
SCHEMBL4672329 0.81 IDH1 (0.33) CES1NCEH1CYP11B1CYP11B2ERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885CYP11B1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.